Advertisement
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,manufacturing and selling innovative cardiac surgical ablation systemsdesigned to create precise lesions, or scars, in cardiac, or heart, tissue.Medical journals have described the adoption by leading cardiothoracicsurgeons of the AtriCure Isolator(R) bipolar ablation system as a treatmentalternative during open-heart surgical procedures to create lesions in cardiactissue to block the abnormal electrical impulses that cause atrialfibrillation, or AF, a rapid, irregular quivering of the upper chambers of theheart. Additionally, medical journals and leading cardiothoracic surgeons havedescribed the AtriCure Isolator(R) system as a promising treatment alternativefor patients who may be candidates for sole-therapy minimally invasiveprocedures. AF affects more than 5.5 million people worldwide and predisposesthem to a five-fold increased risk of stroke.
Advertisement
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,including the new Isolator Synergy(TM) ablation clamps and the AtriCuremultifunctional bipolar Pen, for the ablation, or destruction, of cardiactissue during surgical procedures. Additionally, the FDA has clearedAtriCure's multifunctional Pen for temporary pacing, sensing, stimulating andrecording during the evaluation of cardiac arrhythmias. To date, the FDA hasnot cleared or approved AtriCure's products for the treatment of AF.AtriCure's left atrial appendage exclusion system has not been approved forcommercial use. It is currently being used in clinical evaluations in Europe.Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 [email protected]
SOURCE AtriCure, Inc.
